Regulation of ROCK1/2 by long non-coding RNAs and circular RNAs in different cancer types.
apoptosis
cancer
microRNA
rho-associated protein kinase
signaling
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
21
11
2020
accepted:
19
05
2021
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
ppublish
Résumé
Recent breakthroughs in high-throughput technologies have enabled the development of a better understanding of the functionalities of rho-associated protein kinases (ROCKs) under various physiological and pathological conditions. Since their discovery in the late 1990s, ROCKs have attracted the attention of interdisciplinary researchers due to their ability to pleiotropically modulate a myriad of cellular mechanisms. A rapidly growing number of published studies have started to shed light on the mechanisms underlying the regulation of ROCK1 and ROCK2 via long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in different types of cancer. Detailed analyses have suggested that lncRNAs may be characteristically divided into oncogenic and tumor suppressor lncRNAs. Several exciting recent discoveries have also indicated how different lncRNAs and circRNAs modulate ROCK1/2 and mediate multistep cancer onset and progression. The present review chronicles the major advances that have been made in our understanding of the regulatory role of ROCK1/2 in different types of cancer, and how wide-ranging lncRNAs and circRNAs potentiate ROCK-driven signaling by blocking the targeting activities of tumor suppressor microRNAs.
Identifiants
pubmed: 35399329
doi: 10.3892/ol.2022.13279
pii: OL-23-05-13279
pmc: PMC8987920
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
159Informations de copyright
Copyright: © Farooqi et al.
Déclaration de conflit d'intérêts
The authors declare that they do not have any competing interests.
Références
Nat Rev Mol Cell Biol. 2013 Nov;14(11):699-712
pubmed: 24105322
Exp Cell Res. 2019 Dec 15;385(2):111689
pubmed: 31678169
Oncol Lett. 2019 Mar;17(3):3133-3140
pubmed: 30867743
Oncogene. 2017 Feb 9;36(6):807-819
pubmed: 27399334
J Cell Biochem. 2019 Feb 25;:
pubmed: 30805944
Clin Cancer Res. 2019 Feb 15;25(4):1302-1317
pubmed: 30429198
Cell Rep. 2018 Apr 3;23(1):297-312.e12
pubmed: 29617668
Biomed Pharmacother. 2020 May;125:109882
pubmed: 32006899
Nat Rev Mol Cell Biol. 2020 Mar;21(3):123-136
pubmed: 32020081
Mol Cancer. 2018 May 12;17(1):89
pubmed: 29753317
Int J Mol Med. 2019 Mar;43(3):1157-1166
pubmed: 30592267
Biochem Biophys Res Commun. 2014 Oct 10;453(1):49-56
pubmed: 25251472
Oncol Lett. 2019 Nov;18(5):5392-5398
pubmed: 31620199
Oncol Lett. 2020 Mar;19(3):1899-1905
pubmed: 32194685
J Exp Clin Cancer Res. 2018 Feb 13;37(1):27
pubmed: 29439714
Hum Exp Toxicol. 2021 Feb;40(2):310-324
pubmed: 32830578
Cell Transplant. 2020 Jan-Dec;29:963689720948016
pubmed: 32787581
PLoS One. 2012;7(2):e30733
pubmed: 22319583
Int J Biol Markers. 2020 Mar;35(1):47-56
pubmed: 31960744
FEBS Lett. 2014 Nov 28;588(23):4348-56
pubmed: 25448675
Nat Rev Mol Cell Biol. 2019 Jan;20(1):5-20
pubmed: 30228348
Cell Prolif. 2019 Jul;52(4):e12628
pubmed: 31038266
Cancer Manag Res. 2020 Dec 11;12:12679-12695
pubmed: 33335424
Nat Commun. 2016 Mar 15;7:10982
pubmed: 26975529
BMC Med Genet. 2020 Jan 3;21(1):2
pubmed: 31900116
Cancer Cell Int. 2020 Jun 16;20:249
pubmed: 32550827
Nat Genet. 2007 May;39(5):673-7
pubmed: 17401365
Cell. 2010 Jan 8;140(1):111-22
pubmed: 20085706
J Cell Mol Med. 2020 Nov;24(22):13010-13019
pubmed: 32996285
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Braz J Med Biol Res. 2020 Jan 13;53(1):e8883
pubmed: 31939597
Nat Rev Cancer. 2020 Oct;20(10):573-593
pubmed: 32636489
J Biol Chem. 1995 Dec 8;270(49):29051-4
pubmed: 7493923
J Cell Biochem. 2020 Oct;121(10):4214-4225
pubmed: 31898364
Mol Cell Biochem. 2021 Jan;476(1):199-212
pubmed: 32949310
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
pubmed: 16461460
Onco Targets Ther. 2020 Jun 30;13:6279-6288
pubmed: 32636647
Biochem Biophys Res Commun. 2018 Sep 5;503(2):863-869
pubmed: 29928876
J Cell Physiol. 2019 May;234(5):7266-7278
pubmed: 30362591
J Cell Biochem. 2019 Aug;120(8):13392-13402
pubmed: 30916820
J Biochem. 2001 Jul;130(1):23-31
pubmed: 11432776
Mol Med Rep. 2020 Mar;21(3):1304-1309
pubmed: 31922232
NPJ Precis Oncol. 2020 May 1;4:11
pubmed: 32377572
Mol Cancer. 2020 Nov 5;19(1):156
pubmed: 33153478
Onco Targets Ther. 2020 Sep 30;13:9771-9783
pubmed: 33061456
Biomed Res Int. 2018 Oct 1;2018:4357647
pubmed: 30364063
Nat Rev Genet. 2020 Nov;21(11):671-682
pubmed: 32561862
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9667-72
pubmed: 17535905
J Cell Biochem. 2019 Sep;120(9):14431-14443
pubmed: 31081143
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D135-9
pubmed: 16381831
Genome Biol. 2015 Jan 29;16:20
pubmed: 25630241
Cell Death Dis. 2021 Jan 4;12(1):36
pubmed: 33414429
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
Cell Signal. 2012 Jul;24(7):1420-5
pubmed: 22446004
Science. 2004 Mar 19;303(5665):1800-5
pubmed: 15031492
EMBO J. 1996 Apr 15;15(8):1885-93
pubmed: 8617235
Signal Transduct Target Ther. 2020 Mar 12;5(1):28
pubmed: 32296047
J Cell Biochem. 2018 Nov 26;:
pubmed: 30474879
Mol Ther. 2019 Aug 7;27(8):1350-1363
pubmed: 31324392
Oncogene. 2019 Feb;38(9):1381-1397
pubmed: 30266988
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):810-821
pubmed: 30873868
Cell Signal. 2016 Nov;28(11):1761-72
pubmed: 27519476
J Cell Physiol. 2020 Sep;235(9):5962-5971
pubmed: 31960961
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Nature. 2009 Mar 12;458(7235):223-7
pubmed: 19182780
Nat Genet. 2015 Mar;47(3):199-208
pubmed: 25599403
Nat Rev Genet. 2019 Nov;20(11):675-691
pubmed: 31395983
Ann Hepatol. 2020 Sep - Oct;19(5):535-540
pubmed: 32546442
Cancer Biother Radiopharm. 2020 Feb;35(1):66-71
pubmed: 31702393
Oncol Lett. 2020 Feb;19(2):1305-1309
pubmed: 31966061
J Exp Clin Cancer Res. 2019 Jul 8;38(1):295
pubmed: 31287002
Aging (Albany NY). 2020 Nov 9;12(21):21129-21146
pubmed: 33168781